Genetics of Dilated Cardiomyopathy: Clinical Implications

Authors, Journal, Affiliations, Type, DOI

Overview

A 2018 narrative review of the genetic architecture of dilated cardiomyopathy, written when next-generation sequencing had pushed the gene list past 50 and a pathogenic variant could be found in almost 40% of familial cases. It covers the diagnostic yield and gene frequencies, the overlap between DCM and hypertrophic, restrictive and arrhythmogenic phenotypes, practical rules for testing probands and screening relatives, and a gene-by-gene account of genotype–phenotype correlation. Its central clinical claim is that LMNA was then the only DCM gene with a guideline-level management consequence — an ICD indication — while FLNC, TTN, DSP and DES carried recognisable but not yet guideline-actionable phenotypes. The review is useful now as a baseline against which the 2022–2026 guidelines and ClinGen curation can be read, not as current management guidance.

Keywords

Dilated cardiomyopathy; next-generation sequencing; genotype–phenotype correlation; lamin A/C; filamin C; precision medicine

Key Takeaways

Next-generation sequencing and gene diversity

DCM as a multifaceted disease

Genetic testing in probands

Implications for relatives

Genotype–phenotype correlations

LMNA (lamin A/C)

FLNC (filamin C)

DSP and other desmosomal genes

TTN (titin)

DES (desmin)

PLN (phospholamban)

SCN5A

RBM20

Left ventricular reverse remodelling and prognostic scores

Future perspectives

Limitations of the document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated